Updated:
Capikris Foundation
Founded by former Capital International Senior Vice President Christopher Choe, the Capikris Foundation operates as a hybrid philanthropic and...
Capikris Foundation
Founded by former Capital International Senior Vice President Christopher Choe, the Capikris Foundation operates as a hybrid philanthropic and direct-investment entity. While structured as a private foundation, its operating posture mirrors that of a venture capital firm, with a disclosed footprint in San Francisco, Palo Alto, Toronto, Manchester, and Singapore. The foundation directs capital toward urgent humanitarian relief and patient-capital investments in early-stage biotechnology, aiming to collapse the distance between charitable aid and venture-scale commercial solutions for aging and allergic disease. The foundation's investment strategy concentrates on early-stage health-tech and longevity ventures. Capikris has established a repeat co-investment pattern with aMoon Fund, a prominent Israeli health-tech and life sciences vehicle, and Openspace Ventures, a Southeast Asian venture fund. Confirmed portfolio exposure includes Biofourmis, a Singapore-founded digital therapeutics platform merging AI with remote patient monitoring. Geographic activity spans North America, Israel, and Southeast Asia, with deal flow appearing to route through its Singapore and Palo Alto presences and informed by Christopher Choe's membership in the Singapore Angel Network. Capikris maintains a lean, multi-jurisdictional operating model without a public team-size disclosure. Its direct-deal posture is supplemented by a philanthropic grant-making thesis centered on three mandates: enabling aging in place, advancing allergy awareness and treatment, and funding emergency preparedness and disaster prevention programs. The foundation does not openly solicit external limited partners and shows no evidence of managing third-party capital, preserving full discretion over the pace and concentration of its deployment. Structural differentiation derives from a unified charter that permits commercial venture returns and outright charitable grants to coexist within a single balance sheet, bypassing the silos typical of a family office with a sidecar foundation. The multi-city operational footprint—unusual for a private foundation of its apparent scale—suggests a deliberate sourcing architecture of five local nodes rather than a centralized investment committee.
General information
Firm type
Endowment / Foundation
Location
Region
Asia
Country
United States
City
San Francisco
Corporate office
San Francisco, CA, United States
Additional offices
Palo Alto, CA, United States · Toronto, Canada · Manchester, United Kingdom · Singapore
Principals
Christopher Choe
Founder and Chairman
Sector focus
Frequently asked questions
Who makes investment decisions at the Capikris Foundation?
Investment decisions trace to Founder and Chairman Christopher Choe, who structured the foundation after his tenure as a Senior Vice President at Capital International. The foundation has not disclosed a separate CIO or investment committee. Its deal activity, including co-investments with aMoon Fund and Openspace Ventures, is conducted through a lean, multi-office structure spanning San Francisco, Singapore, Toronto, and Manchester.
How does Capikris Foundation source its venture deals?
Capikris sources opportunities through a geographically distributed presence and Christopher Choe's personal network, including his membership in the Singapore Angel Network. The foundation has established a pattern of repeat co-investing with aMoon Fund, which provides access to Israeli health-tech and longevity startups, and Openspace Ventures, a regional venture firm active in Southeast Asia. Its Singapore and Palo Alto offices are positioned within two globally significant nodes for health-tech and digital-therapeutics deal flow.
Is the Capikris Foundation a family office or a venture capital fund?
Capikris is structured as a private foundation, not a venture capital fund. It does not manage external limited-partner capital and operates with a dual mandate: direct early-stage equity investments in health-tech and longevity companies, and outright charitable grants for disaster relief, allergy treatment, and aging-in-place programs. The foundation imposes no structural separation between its philanthropic and return-seeking activities, distinguishing it from a conventional family office with a sidecar donor-advised fund.
What type of startups does Capikris Foundation target?
The foundation concentrates on early-stage health-tech and longevity biotechnology companies. Its known co-investment partners, aMoon Fund and Openspace Ventures, provide exposure to Israeli life sciences and Southeast Asian digital health platforms, respectively. A disclosed portfolio company is Biofourmis, a digital therapeutics firm using AI for remote patient monitoring, consistent with the foundation's focus on solving aging and allergy-related challenges through commercial ventures.
Where does the underlying capital for the Capikris Foundation come from?
The source of the foundation's endowment has not been publicly disclosed. Founder Christopher Choe's prior role as a Senior Vice President at Capital International, a long-established asset management firm, suggests the philanthropic and venture corpus likely originated from accumulated personal wealth generated during his career in institutional investment management.
Are Capikris Foundation's philanthropic grants separate from its venture investments?
No, the foundation operates a unified charter in which charitable grant-making and venture-stage equity investments draw from a single pool of capital. Its published philanthropic focus areas—aging in place, allergy solutions, and disaster preparedness—align thematically with its venture investments in longevity and digital health platforms like Biofourmis, indicating that grants and equity investments are complementary tools within the same strategic mandate.
Does Capikris Foundation participate in fund commitments or only direct deals?
Available public information points exclusively to direct early-stage venture investments and co-investments alongside firms like aMoon Fund and Openspace Ventures. There is no evidence that Capikris makes blind-pool fund commitments as a limited partner. Its model appears structured for direct, concentrated bets where Christopher Choe can exercise discretion and align the investment directly with the foundation's philanthropic thesis.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on endowments & foundations?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: